Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Abstract

BackgroundWe describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.MethodsFrom 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.ResultsWe analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.ConclusionAmong adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease

“…A recent umbrella review of meta-analyses showed that vaccinations are not associated with an increased risk of IBD [15]. These findings are in line with other studies reporting on the safety of SARS-CoV-2 vaccinations in patients with IBD [16] or rheumatoid arthritis [17,18]. Hadi et al found no differences in adverse events and in prescription of steroids in a matched cohort of IBD and non-IBD patients in a retrospective cohort [19].…”

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

“…The majority of case series analyze the vaccines most commonly employed in Western Europe and the United States particularly Pfizer-BioNTech, Oxford-AstraZeneca and Moderna vaccines. The adverse event profile of these vaccines has been very similar to the general population and severe adverse events have been very rare [7,9,16,17]. Adverse event data from other vaccines in rheumatic patients predominantly employed in Asia, Latin America, and Eastern Europe are very limited.…”

SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls

“…Current efforts are focusing on vaccine responses in SLE. 10,11 Table 1. SLE cohort patients and controls with pre-and/or intra-pandemic SARS-CoV-2 antibodies.…”